Search Result

Results for "

CT26 tumor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) Adenosine Receptor (1) Akt (1) Apoptosis (1) Arf Family GTPase (1) Autophagy (5) Calcium Channel (3) CCR (1) CDK (2) CXCR (1) Cytochrome P450 (1) Fc Receptor (FcR) (1) IFNAR (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (2) Interleukin Related (2) Liposome (1) MHC (1) NF-κB (1) PARP (1) PD-1/PD-L1 (3) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (3) Prostaglandin Receptor (1) Ras (3) Reactive Oxygen Species (ROS) (1) SARS-CoV (1) SHP2 (2) Sirtuin (1) STAT (1) STING (6) TGF-β Receptor (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (4) Infection (6) Inflammation/Immunology (10) Metabolic Disease (1)

By Targets:

TNF Receptor (1)

Adenosine Receptor (1)

Akt (1)

Apoptosis (1)

Arf Family GTPase (1)

Autophagy (5)

Calcium Channel (3)

CCR (1)

CDK (2)

CXCR (1)

Cytochrome P450 (1)

Fc Receptor (FcR) (1)

IFNAR (1)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Integrin (2)

Interleukin Related (2)

Liposome (1)

MHC (1)

NF-κB (1)

PARP (1)

PD-1/PD-L1 (3)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PI3K (3)

Prostaglandin Receptor (1)

Ras (3)

Reactive Oxygen Species (ROS) (1)

SARS-CoV (1)

SHP2 (2)

Sirtuin (1)

STAT (1)

STING (6)

TGF-β Receptor (1)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (32)

Cardiovascular Disease (4)

Infection (6)

Inflammation/Immunology (10)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155971

VISTA-IN-2	Autophagy	Inflammation/Immunology Cancer
VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .

HY-155457

Enpp-1-IN-19	Phosphodiesterase (PDE) STING	Cancer
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC₅₀=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .

HY-P4193

AH1	MHC	Inflammation/Immunology Cancer
AH1 is a MHC class I-restricted tumor-specific antigenic peptide that can be presented by the murine MHC class I molecule L ^d. AH1 is derived from the envelope protein (gp70) of the endogenous ecotropic murine leukemia virus (MuLV) in mice. AH1 acts as an immunodominant CTL epitope in CT26 colon carcinoma. Additionally, AH1 is also an immunodominant CTL target for TS/A murine mammary adenocarcinoma, and its specific CTLs can mediate the killing and rejection of this tumor .

HY-176772

QHL-1618	Others	Cancer
QHL-1618 is a tumor microenvironment-activated drug conjugate. QHL-1618 inhibits the tumor growth in various tumor models, such as HT-1080 xenograft, CT-26 xenograft .

HY-164360

αVβ8-IN-1	Integrin	Inflammation/Immunology Cancer
αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors .

HY-139716

IMD-catechol	NF-κB	Inflammation/Immunology
IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.

HY-169918

SHP2-IN-34	SHP2	Cancer
SHP2-IN-34 (compound A8) is a phenyl urea SHP2 inhibitor with anti-cancer activity. SHP2-IN-34 significantly suppresses tumor growth in CT26 mouse model .

HY-172453

XW-032	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
XW-032 is an apo-IDO1 inhibitor, with an IC₅₀ of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer .

HY-P991481

S-531011	CCR	Cancer
S-531011 is a human IgG1 monoclonal antibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-175195

Adenosine receptor antagonist 6	Adenosine Receptor Interleukin Related IFNAR Cytochrome P450	Inflammation/Immunology Cancer
Adenosine receptor antagonist 6 is an orally active and selective A_2A adenosine receptor (A_2AAR) antagonist, with a K_i of 19.18 nM. Adenosine receptor antagonist 6 inhibits 5’-N-ethylcarboxamide adenosine (NECA) (HY-103173)-mediated cAMP production (IC₅₀ = 0.089 μM) and immunosuppression, while promoting IL-2 and IFN-γ secretion. Adenosine receptor antagonist 6 abolishes the immunosuppressive effects of adenosine on T-cell activation and cytokine release. Adenosine receptor antagonist 6 inhibits tumor growth in a CT26/MC38 xenograft model. Adenosine receptor antagonist 6 can be used for the study of colon cancer .

HY-132192

PD-1/PD-L1-IN-9 2 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride 2 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-P990117

Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10)	Integrin	Cardiovascular Disease Cancer
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived Osteopontin/SPP1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) blocks Angiotensin II (HY-13948)-induced DNA synthesis and collagen gel contraction in cardiac fibroblasts. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) significantly inhibits tumor growth in CT26 or MC38 tumors mice models .

HY-175290

Arf1-GEFs-IN-1	Arf Family GTPase	Cancer
Arf1-GEFs-IN-1 is a potent and orally active ADP-ribosylation factor 1- guanine nucleotide exchange factors (Arf1-GEFs) inhibitor with an IC₅₀ value of 40.85 μM against CT26 cells. Arf1-GEFs-IN-1 primarily mediates tumor regression by triggering anti-tumor immune responses, rather than through direct cytotoxicity. Arf1-GEFs-IN-1 effectively promotes CCL5 expression, demonstrates excellent in vivo efficacy. Arf1-GEFs-IN-1 can be used for the study of colon cancer .

HY-170877

SHP2-IN-35	SHP2 PI3K Akt Autophagy	Cancer
SHP2-IN-35 (Compound 3f) is the inhibitor for SHP2. SHP2-IN-35 exhibits antiproliferative activity in cancer cells RKO, SW480 and CT26 with IC₅₀ of 5.72 μM, 3.71 μM and 1.42 μM, respectively. SHP2-IN-35 inhibits the PI3K-Akt signaling pathway, regulates the cell cycle associated gene expressions, and induces mitochondrial-related autophagy. SHP2-IN-35 inhibits the expression of certain cytokines and chemokines in the tumor microenvironment (TME), thereby regulating the tumor progression .

HY-B0984A

Fendiline 3 Publications Verification	Calcium Channel Ras STING Autophagy	Infection Cardiovascular Disease Cancer
Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC₅₀ of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC₅₀ of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .

HY-B0984

Fendiline hydrochloride 3 Publications Verification	Calcium Channel Ras STING Autophagy	Infection Cardiovascular Disease Cancer
Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC₅₀ of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC₅₀ of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .

HY-N3389

Licoisoflavone A 1 Publications Verification	SARS-CoV Sirtuin CDK Apoptosis	Infection Metabolic Disease Cancer
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-P990680

Anti-Mouse CD40 Antibody (FGK4.5/FGK45)	Transmembrane Glycoprotein TNF Receptor	Infection Inflammation/Immunology Cancer
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

HY-B0984R

Fendiline hydrochloride (Standard)	Calcium Channel Ras STING Autophagy	Infection Cardiovascular Disease Cancer
Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .

HY-P990291

Anti-Mouse CD16.2 Antibody (9E9)	Fc Receptor (FcR)	Inflammation/Immunology Cancer
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation .

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

HY-169859

EP4 receptor antagonist 7	Prostaglandin Receptor Interleukin Related	Inflammation/Immunology Cancer
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC₅₀ value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC₅₀ value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD ⁸⁺ T cells into tumors in a CT26 murine colon cancer model .

HY-172892

PI3K-IN-59	PI3K Reactive Oxygen Species (ROS)	Cancer
PI3K-IN-59 (Compound 3d) is a PI3K inhibitor (IC₅₀: 17.44 μM). PI3K-IN-59 has significant antiproliferative activity and exhibits potent inhibitory effects on breast cancer 4T1 cells (IC₅₀: 3.70 μM) and colon cancer CT26 cells (IC₅₀: 1.98 μM) as well as human breast cancer cells (IC₅₀: 19.72 μM). PI3K-IN-59 exerts a dual anti-tumor mechanism by inhibiting PI3Kα enzymatic activity and triggering the Fenton reaction to generate hydroxyl radicals (•OH). PI3K-IN-59 shows promising anti-4T1 tumor effects and is suitable for synergistic targeting studies in breast and colon cancers .

HY-153546

STING agonist-31	STING	Cancer
STING agonist-31 is a STING agonist, with EC₅₀ values of 0.24 and 39.51 μM for h-STING and m-STING. STING agonist-31 has antitumor efficiency .

HY-147834

STING agonist-9	STING	Cancer
STING agonist-9 (Compound 45) is a potent STING agonist with an EC₅₀ of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity .

HY-139693

PTPN22-IN-1 3 Publications Verification	Phosphatase	Inflammation/Immunology Cancer
PTPN22-IN-1 is a potent PTPN22 inhibitor (IC₅₀=1.4 µM; K_i=0.50 µM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses . From WO2021007491A1 compound L-1.

HY-163081

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to PD-1 and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity .

HY-122891

SB02024 1 Publications Verification	PI3K CXCR STAT	Cancer
SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-136244

PF-06952229 3 Publications Verification	TGF-β Receptor	Cancer
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction.?PF-06952229 is a promising antineoplastic?agent for the study solid tumors, especifically metastatic breast cancer .

Cat. No.	Product Name	Target	Research Area